Fig. 1

Network diagrams of randomized controlled trials for base-case efficacy outcomes in patients with stage II–IV melanoma for a RFS/DFS and b DMFS. DFS disease-free survival, DMFS distant metastasis-free survival, IFN interferon, RFS recurrence-free survival